Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs.
Trends Pharmacol Sci
; 43(12): 1041-1054, 2022 Dec.
Article
in English
| MEDLINE | ID: covidwho-2042159
ABSTRACT
The development of clinically effective drugs that could complement existing vaccines is urgently needed to reduce the morbidity and mortality associated with COVID-19. Drug-metabolizing enzymes, membrane-associated drug transporters, and inflammatory responses can partly determine the safety and efficacy of COVID-19 drugs by controlling their concentrations in both the systemic circulation and in peripheral tissues. It is still unknown how these factors affect how well COVID-19 drugs work in the clinic. We explore how drug metabolism and transport, as well as SARS-CoV-2-associated inflammatory response at disease target sites, may affect the clinical outcomes of COVID-19 drugs. In addition, we provide expert opinion on potential strategies for overcoming the clinical pharmacology and pathophysiological obstacles to improve COVID-19 drug effectiveness.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Trends Pharmacol Sci
Year:
2022
Document Type:
Article
Affiliation country:
J.tips.2022.09.005
Similar
MEDLINE
...
LILACS
LIS